✦ LIBER ✦

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

✍ Scribed by C. van Herpen; F. Eskens; M. de Jonge; I. Desar; L. Hooftman; E. Bone; A. Timmer-Bonte; J. Verweij

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase Ib dose-escalation study to eval

✍ van Herpen, C M L; Eskens, F A L M; de Jonge, M; Desar, I; Hooftman, L; Bone, E 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 306 KB

509 The OPAL Study: A Phase II Study to

✍ Jorge Cortes; Eric Feldman; Karen Yee; Martin Toal; Alison Richardson; Anthony C 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 130 KB

394 A phase I dose escalation and pharma

✍ F. Eskens; L. van Doorn; D. Papadatos-Pastos; P. Debnam; M. Tall; M. Toal; L. Ho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

218 POSTER A phase I dose-escalation stu

✍ E. Calvo; G. Edelman; J. Baselga; E. Kwak; C. Scheffold; L. Nguyen; G.I. Shapiro 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Safety and tolerability of the poly(ADP-

✍ Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Ann 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 215 KB

1468 POSTER A phase 1B, open-label, dose

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB